Solid Tumors

Background Information

Malignant tumors invade and destroy adjacent tissue. As they consist of the body’s own tissue, they are better tolerated by the immune system than other invasive agents such as pathogens. Moreover, tumors actively suppress the immune system. A small group of cells within the tumor – the tumor stem cells – are resistant to chemotherapy and radiotherapy, and have the potential to seed secondary tumors (metastases). There is an urgent need for new therapies for malignancies such as malignant melanoma and colorectal cancer as they are among the most frequent causes of death in industrialized countries. Tumor stem cells display a molecule on their surface called ABCB5. This molecule could potentially be used as a basis for immunotherapies.


« back

Clinical Trials

We are now also recruiting patients for further clinical studies in phase I/IIa with allogeneic ABCB5-positive (ABCB5+) mesenchymal stem cells for the following indications: chronic venous ulcer (CVU), diabetic foot ulcer (DFU) and peripheral arterial occlusive disease (PAOD). For more information click HERE.


Besides the authorization to manufacture a human medicinal product in accordance with § 13 (1) of the German Medicinal Products Act (AMG) for autologous mesenchymal stem cells, TICEBA is also authorized to manufacture a medicinal product for allogeneic mesenchymal as well as allogeneic limbal ABCB5 + stem cells following a recent extension. For more information click HERE.

The Story of Stem Cells

Review our category "The Story of Stem Cells" with the newest topic "Stem cells in wound healing" HERE.